30 results about "Rifapentine" patented technology

The invention discloses a preparation method of rifapentine-carried polycaprolactone microspheres. The preparation method comprises steps as follows: rifapentine crude drugs and polycaprolactone 20 are jointly dissolved in dichloromethane, the mixture is subjected to ultrasonic treatment, and an oil phase is formed; the formed oil phase is dropwise added to a 2% polyvinyl alcohol water solution, mechanically stirred at the rotating speed of 3,000 rpm for 30 min, sealed, left to stand for 30 min and continuously stirred at the rotating speed of 100 rpm for 3 h, and an emulsion is formed; centrifugal treatment is performed, obtained solids are washed with distilled water, centrifugal separation and washing are performed again, finally, drying is performed in a freezing vacuum drier, and the rifapentine-carried polycaprolactone microspheres are obtained and put at the temperature of subzero 4 DEG C in the dark place for storage. The prepared rifapentine-carried polycaprolactone microspheres have round and complete shapes, have a micropore structure on the surface, are good in particle size dispersity and high in drug loading capacity, have a good slow release function and can be used for long-acting interventional therapy of tuberculosis of bones and joints.

The invention relates to a device and a method for preparing a gel microsphere and a gel microsphere in which antitubercular agents can be injected. The device comprises: a porous shower nozzle, a collecting cup, a collecting tubule, a high pressure static generator, a constant current pump, a settling basin, an injection pump and an infiltration electrode. On the basis of a common static liquid drop generating device, the collecting tubule is arranged to form a liquid level flow regulating system, so that a liquid exchange passage exists between the collecting cup and the settling basin and can collect the low-density gel microspheres floating on the liquid level of the collecting cup and rapidly transfer the microspheres to the settling basin. Meanwhile, the built-in infiltration electrode type porous shower nozzle can enable the drug liquid droplet in drug-carrying sol solution to be fully charged, and form a uniform high electric field with the collecting tubule, thus enhancing the atomizing effect of the liquid column of the nozzle and enabling the drug-carrying sol solution to form monodispersity gel microspheres. The gel microsphere in which antitubercular agents can be injected contains rifapentine or rifabutin, made by the device and the method. The gel microsphere is high in yield, and large in drug-carrying capacity, and does not sink down or adhere after drying.

The invention discloses an agent for yellow shoot prevention and control. The agent is applied by a trunk transfusion method. Each 100mL of the agent mainly comprises 0.5-1 gram of penbritin, 0.2-0.5 gram of rifapentine, 0.5-2mL of 1,2-butanediol serving as a stabilizer, 0.1-2mL of glycol serving as an anti-freezing agent, 0.1-2mL of azone serving as a novel permeation promoter, 0.1-2 grams of sodium lignin sulfonate serving as a dispersing agent, 0.1-2 grams of sodium dodecyl benzene sulfonate serving as an emulsifier, 0.1-2mL of DMSO (dimethyl sulfoxide) serving as a co-solvent and the rest deionized water supplemented to reach 100mL. Different bactericides are reasonably mixed by two sterilization mechanisms according to the objective requirement of yellow shoot prevention and control, the agent can achieve complementary advantages and has the advantages of high efficiency, low toxicity, safety, economization and multifunction, and yellow shoot can be more effectively prevented and controlled.

The slow released antituberculotic preparation is implanting agent or injection with slow releasing of medicine in the local tuberculosis focus to maintain the local effective medicine concentration while lowing the systemic toxicity. The slow released injection consists of slow released microsphere and solvent. The slow released microsphere consists of slow releasing supplementary material and antituberculotic selected from rifampicin, rifamycin, rifapentine and/or rifabutine. The solvent is special solvent containing suspending agent of carboxymethyl cellulose sodium, etc. and has viscosity of 100-3000 cp at 20-30 deg.c. The slow releasing supplementary material is selected from EVAc, PLA, PLGA, etc. The slow released preparation may be prepared with slow released microsphere. The present invention has obvious and unique treating effect on various kinds of intractable tuberculosis.

The invention discloses a method for detecting an anti-tuberculosis drug in serum by an ultra-high performance liquid chromatography-tandem mass spectrometry technology. The antitubercular drug comprises cycloserine (CYS), pyrazinamide (PZN), isoniazid (INZ), p-aminosalicylic acid (P-ASA), ethiisonicotinamide (ETN), ethambutol (ETB), clofazimine (CFM), bedaquiline (BDQ), rifampicin (RFP), rifbutine (RFB) and rifapentine (RFT). The method includes: detecting the content of the antituberculosis drug in the pretreated serum by adopting an ultra-high performance liquid chromatography-tandem mass spectrometry method, performing quantifying by utilizing a mass spectrometry isotope internal standard method, establishing a calibration curve by taking the concentration ratio of the standard substance to the internal standard substance as an X axis and the peak area ratio of the standard substance to the internal standard substance as a Y axis, and calculating the concentration of the target drug in the serum; the method is high in sensitivity, strong in specificity and simple in pretreatment process, separation and detection of the anti-tuberculosis drugs in serum are completed within 5 min, and a simple and rapid detection method is provided for clinical concentration monitoring of the anti-tuberculosis drugs.

The invention discloses a preparation method of rifapentine, and the steps are as follows: rifamycin S is used as a starting material for reacting with dihydroxy methyl tert-butyl amine in a first organic solvent to convert into intermediate rifaoxazine; a catalyst and a reductant are added into a second organic solvent for hydrolysis ring opening of the intermediate rifaoxazine; a rifapentine solution is obtained by condensation of a rifaoxazine hydrolysis product and 1-amino-4-cyclopentyl piperazine; and a rifapentine finished product is obtained by filtration, segmented crystallization at multistage crystallization temperature, first separation, washing, second separation, drying, soaking, third separation, drip washing, spin drying, sieving, drying, and powder mixing refining processes of the rifapentine solution. The preparation method adopts the reductant which can play a role in anti oxidation; different crystallization temperature is adopted in the segmented crystallization process; and by combination with the adding of a crystallization solvent, the crystalline polymorph is uniform, the particles are uniform, the stability is good, and the defects of high impurity content and nonuniform particles of rifapentine processes in the prior art can be solved.

Oral administration forms are described for the controlled release of an antibiotic selected from the group consisting of rifampicin, rifabutin, rifapentine, rifalazil and mixtures thereof, for treating bacterial infections of the gastrointestinal tract, in particular travellers' diarrhoea, hepatic encephalopathy, ulcerative colitis, irritable bowel syndrome (IBS), Crohn's disease, and IBD (inflammatory bowel disease) in general. Moreover, said oral administration forms allow reduction of the amounts of antibiotic to be taken, with respect to the known administration forms and without reaching blood concentrations such as to select resistant strains of tuberculosis mycobacteria.

The invention provides a preparation method of high-purity rifapentine, which is characterized by comprising the following steps: 1. carrying out a cyclization reaction on rifamycin S acid, acid and dimethyloltert-butylamine in an N, N-dimethylformamide solvent; 2, pouring the reaction solution into acid water, standing, and filtering to obtain a rifaxizine filter cake; 3, adding urea, n-butyl alcohol, Vc and sodium carbonate into the rifaxizine filter cake for a ring-opening reaction; 4, after the reaction is completed, increasing the purity to 1-amino-4-cyclopentylpiperazine for a condensation reaction until the reaction is completed so as to obtain a rifapentine reaction solution; and step 5, dropwise adding acid water into the rifapentine reaction solution, stirring, stopping heating after crystallization, lowering the rotating speed after turning red, cooling after dropwise adding is finished, filtering to obtain the filter cake, and carrying out secondary recrystallization on thefilter cake. According to the preparation method of the high-purity rifapentine, provided by the invention, the maximum single impurity of the rifapentine can be controlled within 0.1%, and the residual n-butyl alcohol and the residual ethanol can be controlled within 0.5%.

The present invention features an antibacterial composition comprising 1) a composition A comprising polymyxin B and trimethoprim; and 2) an antibiotic agent selected from the group consisting of rifampicin, rifabutin, rifapentine, rifaximin, pefloxacin mesylate, sparfloxacin, sarafloxacin HCl, tobramycin, lomefloxacin, besifloxacin, danofloxacin mesylate, enrofloxacin, nadifloxacin and clinafloxacin, a topical pharmaceutical thereof, and a method of treating bacterial infections using mixtures of 1 and 2.

The invention provides a pharmaceutical composition for treating pulmonary tuberculosis, which comprises a main drug and an auxiliary drug, and the main drug comprises rifapentine and glucurolactone. The main drugs comprise the following components in parts by weight: 0.5-5 parts of rifapentine and 0.5-10 parts of glucurolactone, and the weight ratio of the rifapentine to the glucurolactone is (0.375-0.75): 1. According to the pharmaceutical composition for treating pulmonary tuberculosis disclosed by the invention, the rifapentine and the glucurolactone are prepared into the pharmaceutical composition according to a reasonable proportion, so that the abnormal liver function rate of a patient is reduced.

Provided herein are ophthalmic pharmaceutical formulations comprising a rifamycin compound. Also provided herein are methods of treating ocular diseases or disorders by administering such ophthalmic formulations. This invention relates generally to pharmaceutical compositions or formulations suitable for administration to an eye. In some aspects, this invention relates to ophthalmic pharmaceutical compositions or formulations comprising one or more rifamycin compounds selected from the group consisting of rifampicin, rifabutin, rifapentine. In one aspect, the invention relates to methods of treating an ocular disease, disorder or condition comprising administering to a patient in need thereof an ophthalmic composition comprising an effective amount of a rifamycin compound selected from the group consisting of rifampicin, rifabutin, rifapentine, and rifaximin.

The invention, relating to both the technical field of biology and medicine, discloses rifapentine sustained-released microspheres and a preparation method thereof. The rifapentine sustained-released microspheres disclosed herein have high drug loading capacity, good entrapment efficiency, and good sustained action by in vitro release test. The rifapentine sustained-released microspheres disclosed herein can be directly implanted into tuberculosis local focus to conduct regional continuous chemotherapy to let the tuberculosis focus position have large drug amount, high drug concentration, long duration, large effect, good local curative effect, little amount of the drug distributed to the whole body, and low plasma concentration, thus the curative effect is raised, and the effect of adverse reaction is significantly reduced, so that good treatment of patients (severe liver and kidney dysfunction, combination of a plurality of systemic diseases, severe malnutrition) who can not endure anti-tuberculosis chemotherapy can be achieved. The preparation method of the rifapentine sustained-released microspheres has the advantages of low cost, simple operation, and convenient, simple and repeatable method, and can generate huge economic benefits.

The invention belongs to the field of rifamycin adsorption materials, and particularly relates to a polyphenol modified gamma type alumina-based porous carbon composite material, a preparation method and application. The polyphenol modified gamma type alumina-based porous carbon composite material is a gamma-(Al2O3) 1.333/CBT-900 composite material, and the polyphenol modified gamma type alumina based porous carbon composite material is composed of nano particles with the length of 100-200 nm and the uniform size. The polyphenol modified gamma type alumina-based porous carbon composite material gamma-Al2O3/CBT-900 is used as a novel rifapentine molecule removal material, can play a synergistic role of nano-porous carbon and metal oxide, further improves the specific surface area of the material, and increases the contact area and adsorption sites of the material and rifapentine. When being used as a novel adsorbent of rifapentine, the composite material shows good adsorption performance.